10 results about "Oral route" patented technology

The application provides a copper selenide-halloysite-mannose composite drug delivery system, which comprises a carrier, the carrier is halloysite nanotubes (HNTs), copper selenide nanoparticles (CuSe) are in situ grown on the tube wall of the halloysite nanotubes to form a composite CuSe@HNTs; and mannose is loaded in the lumen of the CuSe@HNTs to form a composite drug delivery system CuSe@HNTs@ME. The application also provides a preparation method and application of the copper selenide-halloysite-mannose composite drug delivery system. The drug delivery system can maintain stability in a gastric acid environment, directly reaches an intestinal inflammation site through an oral route, and significantly reduces intestinal inflammation symptoms.

The application discloses a novel coronavirus vaccine based on controllable secretion expression of attenuated salmonella, a preparation method and application thereof, and is used for preventing the novel coronavirus. The application constructs controllable, stable and secretory expression plasmids of different antigen domain proteins of the novel coronavirus and attenuated salmonella expression strains of the different antigen domain proteins; a plurality of attenuated salmonella antigen presentation strains which can controllably and secretively express in antigen presenting cells are mixed, and through an oral route, the plurality of different antigen proteins can be efficiently secretively expressed in the antigen presenting cells by means of the unique secretion system of the attenuated salmonella after administration. The secretively expressed antigenic proteins can be effectively processed and presented by the antigen presenting cells, and finally the immune system is activated / regulated, higher titer antibodies are generated, and the vaccine plays a role.

The present invention in particular relates to a method for reducing virus shedding, colonization of lymphoid tissue, and / or lymphoid depletion caused by or associated with a porcine circovirus type 2 (PCV2) infection in a pig, the method comprising administering orally to the pig an immunogenic composition comprising non-replicating PCV2 antigen. In one example, an immunogenic composition is administered via the oral route to a pig, wherein the immunogenic composition comprises a recombinantly produced and purified PCV2 ORF2 protein. This allows to simply reduce virus shedding, colonization of lymphoid tissue, and / or lymphoid depletion caused by associated with a PCV2 infection in the pigs, while simultaneously reducing the propensity for adverse reactions, eliminating the risk of injection site reactions, avoiding pain, and putting less stress on the animals.

The invention relates to a pharmaceutical composition in the form of a spheroid dosage form that can be absorbed by oral route, said spheroid containing, as the sole active ingredient with antimalarial activity, a therapeutically effective amount of at least 200 mg of artesunate, for use as a drug.

Immunogenic formulations by oral route comprising: i) one or more chimeric proteins consisting of an immunologically associated antigen from a pathogenic microorganism of the pig and a molecular adjuvant CD154 from the pig; ii) an adjuvant selected from the cyclic dinucleotide monophosphate family; and iii) an excipient acceptable for oral immunization. A method of inducing an immune response against a pathogen characterized in that an immunogenic formulation comprising: i) one or more chimeric proteins formed from an immunologically related antigen from a swine pathogen fused with a molecular adjuvant CD154 from the swine is administered to the swine by oral route; and ii) an adjuvant selected from the cyclic dinucleotide monophosphate family.

The present invention relates to a method of inducing an immune response in a subject comprising orally administering to the subject an immunogenic composition comprising a non-replicating viral antigen. In one example, an immunogenic composition is administered to a pig by an oral route, where the immunogenic composition comprises a recombinant viral capsid protein capable of forming a virus-like particle. This allows for simple induction of immune responses in pigs while reducing the propensity of adverse reactions, eliminating the risk of reactions at the injection site, avoiding pain, and reducing stress in animals.

The present invention relates to a composition of a long-acting bioadhesive endoparasiticide gel based on an isoxazoline alone or in combination with other antiparasitic agents, having a high degree of adhesion to oral mucosa and high palatability greatly facilitating the dosing thereof, and to methods for preparing the same. Ectoparasitosis is a parasitic disease caused by fleas, ticks and mites that infest the surface layers of the skin in small animals. Control of this illness is of great importance and advantageously achievable through the use of appropriate antiparasitic agents such as isoxazolines, being a chemical compound widely administered by oral route in tablet form due to the organoleptic and physicochemical characteristics of the compositions known up to the present. The present invention demonstrates that it is possible to administer isoxazolines in the pharmaceutical form of an oral gel at concentrations of up to 20.0% weight / volume, overcoming the organoleptic and physicochemical restrictions of the compositions known up to the present. Factors never heretofore included in oral endoparasiticide compositions based on isoxazolines, presenting a wide differential advantage compared with the compositions known up to the present.

The present application provides a kind of lactobacillus gasseri LN32 and lactobacillus crispatus LN70 containing probiotic composition and application in reducing the risk of vaginal infection, belong to microbial application technical field.Containing 4 strains of probiotics, including lactobacillus plantarum LN66, lactobacillus rhamnosus LN56, lactobacillus gasseri LN32 and lactobacillus crispatus LN70.The probiotic composition is realized by oral route, vaginal flora reconstruction, inhibit the reproduction of gardnerella vaginalis and candida albicans, increase lactobacillus colonization, eliminate abnormal leucorrhea, vaginal burning and itching, frequent urination, urgency and pain.The probiotic composition is combined with conventional carrier, applied to prepare food, dietary supplement or drug for preventing and / or treating vaginal and urethral microecological disorder, bacterial vaginitis, mycotic vaginitis and urethral infection, and then the present application realizes inhibiting harmful bacteria in vagina, reconstructing vaginal flora to reduce the risk of vaginal infection and reduce the risk of urethral infection.

The invention belongs to the field of biological medicine, and particularly provides novel application of an imidazole pyridine derivative, and the chemical formula of the imidazole pyridine derivative is 4-{5 '-[3'-propyl-2 '-[3' '-(1' '-methyl) indolyl]-imidazole [4, 5-b] pyridine] group} morpholine. The invention provides an application of the imidazole pyridine derivative or the pharmaceutically acceptable salt thereof in preparation of a medicine for treating pulmonary fibrosis. When the compound disclosed by the invention is used for treating the pulmonary fibrosis, after animals with the pulmonary fibrosis are subjected to oral administration and inhalation administration, the lung function, the lung index, the lung tissue lesion and the fibrosis degree of model animals in different administration groups are obviously improved, so that an appropriate dosage of X22 has a treatment effect on the animals with the pulmonary fibrosis; and the pulmonary fibrosis improvement effect of the X22 inhalation way is obviously better than that of the X22 oral administration way and the existing conventional medicine.

Methods and apparatus for use in continuous manufacturing (CM) of engineered particulate formulations, including formulations containing therapeutic protein or mAbs, are provided. The resulting products have wide ranges of application, and may be formulated for pulmonary drug delivery systems. Pulmonary drug delivery systems produced according to the CM systems / methods may be used instead of conventional IV, SQ or oral route of administrations.